Combined estrogenic and androgenic hormone therapy in advanced breast cancer

F on advanced breast cancer have been observed repeatedly since the early reports of Haddow and co-workers.237 The incidence of improvement has varied from 18 to 58.5% of dian for these series was 36%. In 8 of these reports comparison was made between the effects of estrogenic and androgenic hormones. Seven of 8 reports suggested that the estrogenic hormone was superior to the androgenic hormone. Among these, in a pioneering effort to conduct a large collaborative study, the Therapeutics Trial Committee (later designated the Committee on Research) of the American Medical Association reported a retrospective study of 944 patients receiving estrogenic or androgenic hormones. The estrogens induced a higher frequency of regressions (38%) than did the androgens Many of these studies lacked the rigid requirements for statistical analysis, primarily in the lack of randomized selection of patients for therapy. In 1957 the Co-operative Breast Cancer Group of the Cancer Chemotherapy National Service Center (CCNSC), National Cancer Institute, Public Health 12 series reviewed.1, 4-6, 8, 0, 11-15, 17-18 The me-(27%)e4